This topic contains a solution. Click here to go to the answer

Author Question: Refer to Figure 7-2. At the market equilibrium, the deadweight loss is equal to A) 0. B) 500,000. ... (Read 126 times)

soccerdreamer_17

  • Hero Member
  • *****
  • Posts: 552
Refer to Figure 7-2. At the market equilibrium, the deadweight loss is equal to
 
  A) 0. B) 500,000. C) 1,000,000. D) 2,000,000.

Question 2

Refer to Figure 2-13. What is the opportunity cost of producing 1 ton of coconuts in Costa Rica?
 
  A) 3/8 of a ton of pineapples B) 2/3 of a ton of pineapples
  C) 1 1/2 tons of pineapples D) 100 tons of pineapples



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

macagn

  • Sr. Member
  • ****
  • Posts: 345
Answer to Question 1

D

Answer to Question 2

B




soccerdreamer_17

  • Member
  • Posts: 552
Reply 2 on: Jun 29, 2018
YES! Correct, THANKS for helping me on my review


jordangronback

  • Member
  • Posts: 339
Reply 3 on: Yesterday
Gracias!

 

Did you know?

The U.S. Preventive Services Task Force recommends that all women age 65 years of age or older should be screened with bone densitometry.

Did you know?

The Centers for Disease Control and Prevention (CDC) was originally known as the Communicable Disease Center, which was formed to fight malaria. It was originally headquartered in Atlanta, Georgia, since the Southern states faced the worst threat from malaria.

Did you know?

As of mid-2016, 18.2 million people were receiving advanced retroviral therapy (ART) worldwide. This represents between 43–50% of the 34–39.8 million people living with HIV.

Did you know?

Cutaneous mucormycosis is a rare fungal infection that has been fatal in at least 29% of cases, and in as many as 83% of cases, depending on the patient's health prior to infection. It has occurred often after natural disasters such as tornados, and early treatment is essential.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library